Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
This inspection continues a series of successful inspections by Swissmedic in Vionnaz with the first inspection in 2015 followed by 2016, 2017 and 2020.
This new facility integrates multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
ExoBrite antibody conjugates are validated and optimized for bright and specific detection of exosome markers
Site Enhances New Modality CRDMO Platform Capacity for Customers
Subscribe To Our Newsletter & Stay Updated
